Logo image of KNE.CA

KANE BIOTECH INC (KNE.CA) Stock Fundamental Analysis

TSX-V:KNE - CA4838092084 - Common Stock

0.0425 CAD
+0 (+6.25%)
Last: 8/29/2025, 7:00:00 PM
Fundamental Rating

2

KNE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 24 industry peers in the Biotechnology industry. KNE has a bad profitability rating. Also its financial health evaluation is rather negative. KNE has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year KNE was profitable.
In the past year KNE has reported a negative cash flow from operations.
In the past 5 years KNE reported 4 times negative net income.
In the past 5 years KNE always reported negative operating cash flow.
KNE.CA Yearly Net Income VS EBIT VS OCF VS FCFKNE.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M 6M

1.2 Ratios

KNE has a better Return On Assets (225.92%) than 100.00% of its industry peers.
Industry RankSector Rank
ROA 225.92%
ROE N/A
ROIC N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KNE.CA Yearly ROA, ROE, ROICKNE.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K 20K 30K 40K 50K

1.3 Margins

KNE's Profit Margin of 255.02% is amongst the best of the industry. KNE outperforms 100.00% of its industry peers.
KNE has a Gross Margin of 35.82%. This is in the better half of the industry: KNE outperforms 70.83% of its industry peers.
In the last couple of years the Gross Margin of KNE has grown nicely.
Industry RankSector Rank
OM N/A
PM (TTM) 255.02%
GM 35.82%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
KNE.CA Yearly Profit, Operating, Gross MarginsKNE.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

KNE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KNE has more shares outstanding
The number of shares outstanding for KNE has been increased compared to 5 years ago.
The debt/assets ratio for KNE has been reduced compared to a year ago.
KNE.CA Yearly Shares OutstandingKNE.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
KNE.CA Yearly Total Debt VS Total AssetsKNE.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -21.22, we must say that KNE is in the distress zone and has some risk of bankruptcy.
KNE has a Altman-Z score (-21.22) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.22
ROIC/WACCN/A
WACC12.27%
KNE.CA Yearly LT Debt VS Equity VS FCFKNE.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M -4M -6M -8M -10M

2.3 Liquidity

A Current Ratio of 0.56 indicates that KNE may have some problems paying its short term obligations.
The Current ratio of KNE (0.56) is worse than 62.50% of its industry peers.
KNE has a Quick Ratio of 0.56. This is a bad value and indicates that KNE is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.49, KNE is doing worse than 62.50% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.56
Quick Ratio 0.49
KNE.CA Yearly Current Assets VS Current LiabilitesKNE.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 174.50% over the past year.
KNE shows a strong growth in Revenue. In the last year, the Revenue has grown by 54.91%.
KNE shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 4.21% yearly.
EPS 1Y (TTM)174.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.32%
Revenue 1Y (TTM)54.91%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%694.8%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KNE.CA Yearly Revenue VS EstimatesKNE.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M 2.5M

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 0.85, the valuation of KNE can be described as very cheap.
100.00% of the companies in the same industry are more expensive than KNE, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 27.13, KNE is valued rather cheaply.
Industry RankSector Rank
PE 0.85
Fwd PE N/A
KNE.CA Price Earnings VS Forward Price EarningsKNE.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KNE.CA Per share dataKNE.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.02 -0.02 0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KNE!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KANE BIOTECH INC

TSX-V:KNE (8/29/2025, 7:00:00 PM)

0.0425

+0 (+6.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-28 2025-08-28
Earnings (Next)11-26 2025-11-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners39.86%
Ins Owner ChangeN/A
Market Cap7.05M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 0.85
Fwd PE N/A
P/S 2.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.05
EY117.65%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0.01
BVpS-0.01
TBVpS-0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 225.92%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 255.02%
GM 35.82%
FCFM N/A
ROA(3y)28.88%
ROA(5y)-12.96%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.83%
GM growth 5Y3.08%
F-Score4
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60.15%
Cap/Sales 5.23%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.56
Quick Ratio 0.49
Altman-Z -21.22
F-Score4
WACC12.27%
ROIC/WACCN/A
Cap/Depr(3y)31.77%
Cap/Depr(5y)88.96%
Cap/Sales(3y)13.66%
Cap/Sales(5y)14.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)174.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.32%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)54.91%
Revenue growth 3Y8.98%
Revenue growth 5Y4.21%
Sales Q2Q%694.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y37.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33.11%
OCF growth 3YN/A
OCF growth 5YN/A